Two pituitary hormones known as LH and FSH help clinicians diagnose primary, secondary, and subclinical hypogonadism alongside standard total testosterone blood tests.
A man opens his lab portal after weeks of persistent fatigue and low sex drive. His total testosterone result is flagged as low, but right below it sit two other markers: luteinizing hormone (LH) and follicle-stimulating hormone (FSH). One number is slightly above the reference range, while the other sits near the bottom.
Looking at these values without context can cause immediate confusion. A low testosterone reading tells you what is present in the bloodstream, but it does not explain why that level is low.
To understand the complete picture, clinicians look at LH and FSH. These two hormones act as the master messengers between the brain and the testes.
Examining LH and FSH alongside testosterone allows clinicians to locate where a signaling breakdown might exist. This definitive guide explains how these hormones function together, how clinicians interpret distinct laboratory patterns, and what the evidence says about male reproductive health.
This resource is created strictly for educational purposes and is not individual medical advice. Hormone laboratory ranges and clinical presentations vary significantly among individuals.
Never use this information to self-diagnose, self-treat, or alter prescribed medications. Always consult a qualified physician or endocrinologist for personalized diagnostic evaluations, interpretation of blood tests, and treatment planning.
LH and FSH are pituitary gonadotropins that direct testicular function. LH signals the Leydig cells to produce testosterone, while FSH supports Sertoli cells and sperm development.
A testosterone test measures circulating hormone output. In contrast, LH and FSH reveal the strength of the brain's regulatory signals to the testes.
High LH alongside confirmed low testosterone points toward a primary testicular issue. In this scenario, the brain sends strong signals, but the testes cannot respond adequately.
Low or inappropriately normal LH alongside low testosterone suggests a secondary or central issue. Here, the brain fails to send an adequate compensatory signal.
FSH provides insight into the spermatogenic side of testicular health. However, FSH is not a direct sperm count and cannot replace a formal semen analysis.
Exogenous testosterone therapy suppresses both LH and FSH secretion. This suppression lowers intratesticular testosterone and can significantly impair sperm production.
A single blood draw is never sufficient for diagnosis. Clinical guidelines require repeat morning fasting tests, symptom evaluation, and a thorough medical history.
The production of testosterone and sperm is managed by a biological communication network called the hypothalamic-pituitary-gonadal (HPG) axis. This axis functions through a continuous feedback loop between the brain and the reproductive organs. When the system operates smoothly, it keeps hormone levels within an appropriate physiological window.
The process begins in the hypothalamus, a specialized region at the base of the brain. The hypothalamus releases gonadotropin-releasing hormone (GnRH) in periodic pulses throughout the day and night.
GnRH travels a short distance to the anterior pituitary gland. Upon receiving GnRH pulses, the pituitary gland produces and secretes two key gonadotropins: luteinizing hormone and follicle-stimulating hormone.
Once released into the general bloodstream, LH and FSH travel to the testes. In the testes, they bind to specific receptors on distinct cell populations:
The system relies on negative feedback to maintain balance. As Leydig cells produce testosterone, that testosterone circulates back to the brain. In the hypothalamus and pituitary, testosterone and its metabolite estradiol signal the brain to reduce GnRH and LH secretion.
Similarly, Sertoli cells produce a hormone called inhibin B in response to FSH activity and
developing sperm. Inhibin B travels back to the pituitary to suppress further FSH secretion.
This feedback loop creates an ongoing homeostatic balance. If testicular testosterone output drops, the brain detects the deficit and increases its release of LH. If the testes produce abundant testosterone, the brain dials back its signaling.
Understanding this dynamic feedback mechanism is essential. It explains why measuring LH and FSH is critical whenever circulating testosterone is abnormal. You can read more about these fundamental mechanisms in our guide to testosterone fundamentals and hormonal function.
To make sense of a comprehensive hormone panel, each biomarker must be understood in isolation before evaluating how they interact. Clinicians evaluate a cluster of related markers to form an accurate picture of hormonal and reproductive health.
Total testosterone measures the cumulative amount of testosterone circulating in the bloodstream. This includes hormone bound tightly to sex hormone-binding globulin (SHBG), hormone bound loosely to albumin, and unbound free testosterone.
Circulating testosterone follows a circadian rhythm in healthy men, peaking in the early morning hours and declining toward the evening. For this reason, professional guidelines require morning fasting blood collections to evaluate baseline levels.
Total testosterone reflects overall androgen production. However, it does not reveal the underlying signaling health of the pituitary or the state of sperm production on its own.
Not all circulating testosterone is immediately available to target tissues. Roughly 40 to 70 percent of total testosterone is bound tightly to SHBG and is biologically inactive at most cellular receptors.
Another 30 to 50 percent binds weakly to albumin. The remaining 1 to 3 percent circulates unbound as free testosterone.
Bioavailable testosterone refers to the sum of free testosterone and albumin-bound testosterone. Clinicians often measure or calculate free testosterone when a patient has borderline total testosterone, or when conditions like obesity, liver disease, or thyroid issues alter SHBG levels.
Free testosterone provides a closer approximation of active tissue exposure. Yet, like total testosterone, it represents an output rather than an upstream regulatory signal.
Luteinizing hormone is a glycoprotein hormone synthesized and secreted by gonadotroph cells in the anterior pituitary gland. Its primary target in men is the Leydig cell population in the testicular interstitium.
LH secretion is pulsatile, meaning it is released into the blood in discrete bursts every 90 to 120 minutes. Because of this pulsatility, single blood tests show modest fluctuations throughout the day.
In clinical evaluation, LH serves as a gauge of pituitary demand. When circulating testosterone is deficient, a healthy pituitary increases LH output to stimulate the testes. When circulating testosterone is excessive, LH secretion drops.
Follicle-stimulating hormone is also produced by the anterior pituitary gland in response to GnRH. Unlike LH, which focuses on androgen production, FSH directs its activity toward the seminiferous tubules where sperm cells develop.
FSH binds to Sertoli cells to initiate and support spermatogenesis. It stimulates these cells to secrete androgen-binding protein (ABP), which keeps local testosterone concentrations inside the testes significantly higher than in general circulation.
FSH also stimulates Sertoli cells to produce inhibin B. Inhibin B serves as the primary negative feedback signal that tells the pituitary to regulate FSH release. Persistent alterations in FSH often point to changes in the spermatogenic capacity of the seminiferous tubules.
Sex hormone-binding globulin is a glycoprotein produced primarily by the liver. It binds testosterone, dihydrotestosterone (DHT), and estradiol with high affinity.
Alterations in SHBG directly affect the proportion of total testosterone that remains free and unbound. High SHBG can cause total testosterone to appear normal while free testosterone is low.
Conversely, low SHBG can cause total testosterone to look low while free testosterone remains within an adequate range. Evaluating SHBG alongside gonadotropins helps prevent misinterpreting a patient's true androgen status. You can learn more about these laboratory nuances in our overview of testosterone testing and biomarkers.
Prolactin is a peptide hormone produced by the anterior pituitary gland. While primarily associated with lactation in women, prolactin exists in low concentrations in men.
When prolactin is excessively elevated, a condition known as hyperprolactinemia, it directly suppresses the pulsatile release of GnRH from the hypothalamus. This suppression leads to decreased LH and FSH secretion, resulting in secondary hypogonadism.
Measuring prolactin is a critical step when evaluating low testosterone accompanied by low or inappropriately normal gonadotropins.
Interpreting hormone test results requires looking at the relationship between the pituitary signals (LH and FSH) and the testicular output (testosterone). Rather than viewing each biomarker as a standalone value, clinicians categorize findings into recognized physiological patterns.
These patterns help localize where the underlying issue resides along the HPG axis.
Primary hypogonadism, also called hypergonadotropic hypogonadism, occurs when the root cause of hormone deficiency lies within the testes themselves.
In primary hypogonadism, the hypothalamus and pituitary are functioning correctly. The brain senses that circulating testosterone is low and attempts to correct the problem. It releases increased amounts of GnRH and LH to stimulate the Leydig cells.
However, because the testicular tissue is damaged, dysfunctional, or absent, the Leydig cells cannot produce enough testosterone despite the strong upstream signal.
Possible causes of primary hypogonadism include:
When a clinician identifies low testosterone alongside elevated LH and FSH, the diagnostic focus centers on testicular health and potential structural or genetic etiologies.
Secondary hypogonadism, also known as hypogonadotropic hypogonadism, occurs when the failure originates in the hypothalamus or pituitary gland.
In this scenario, the testes may be completely capable of producing testosterone, but they are not receiving the necessary instructions from the brain. The pituitary fails to produce an adequate surge of LH and FSH to prompt testicular synthesis.
The concept of an inappropriately normal LH or FSH is critical to understand. If a man's total testosterone is 180 ng/dL (well below standard adult reference ranges), a normal regulatory system should produce a high LH level to compensate.
If the lab report shows an LH value of 3.5 IU/L (which falls inside a typical reference interval of 1.5 to 8.5 IU/L), that number is not truly normal. It is inappropriately normal because it represents an inadequate physiological response to severe testosterone deficiency.
Secondary hypogonadism can arise from structural, functional, or systemic causes:
Recognizing a secondary pattern prompts clinicians to look upstream. This often involves checking prolactin levels, evaluating metabolic health, reviewing medications, and considering pituitary imaging. To understand how lifestyle and systemic factors influence these central signals, consult our guide on lifestyle and natural testosterone support.
Some men present with a pattern where circulating testosterone is within the normal range, but LH is elevated.
This state is often referred to as compensated hypogonadism. In this scenario, the Leydig cells are experiencing early functional decline or resistance.
To maintain normal testosterone concentrations in the blood, the pituitary gland must work harder, secreting higher amounts of LH. The elevated LH successfully drives the struggling Leydig cells to produce enough testosterone to keep blood levels inside the normal range.
Compensated hypogonadism can be an early indicator of progressive primary testicular decline. However, it does not automatically require hormone replacement. Clinicians generally monitor these patients over time, evaluating symptoms, overall health, and repeat lab values before determining if intervention is necessary.
In some clinical evaluations, particularly during fertility assessments, a man may show completely normal testosterone and normal LH, but significantly elevated FSH.
This pattern suggests that Leydig cell function and overall androgen production remain intact, but Sertoli cell function or seminiferous tubule architecture is impaired.
When spermatogenesis is severely disrupted, Sertoli cells produce lower amounts of inhibin B. Without sufficient inhibin B feedback, the pituitary increases its production of FSH.
An isolated high FSH often correlates with impaired sperm production, such as severe oligospermia (very low sperm count) or non-obstructive azoospermia (absence of sperm in the ejaculate).
While an elevated FSH provides a valuable clinical clue, it is not a direct measure of sperm count. It must always be interpreted alongside a formal semen analysis and physical examination.
Men who are currently using prescribed testosterone replacement therapy (TRT) or illicit anabolic-androgenic steroids present with a distinct laboratory signature.
When external androgens enter the bloodstream, the hypothalamus and pituitary detect high circulating androgen and estrogen levels. The negative feedback system responds by shutting down endogenous GnRH, LH, and FSH secretion.
Without LH and FSH signaling, the testes cease their internal testosterone production and pause spermatogenesis. Over time, the Leydig and Sertoli cells become dormant, often leading to testicular shrinkage and severe reductions in sperm output.
This suppressed pattern is an expected physiological consequence of exogenous hormone use, rather than an underlying organic disease of the pituitary. Understanding this mechanism is vital for men considering therapy who also wish to preserve their fertility. For more detailed research on treatment impacts, review our hub on TRT and emerging research.
The following breakdown summarizes how clinicians review these biomarker relationships. It serves as an educational framework for understanding physiological patterns, not as a diagnostic tool.
To see how these concepts apply in clinical practice, consider the following illustrative teaching examples. These scenarios demonstrate how medical providers reason through complex laboratory data alongside individual clinical histories.
A 42-year-old man visits his physician reporting persistent fatigue, reduced physical stamina, and difficulty maintaining muscle mass. Two separate morning fasting blood tests confirm a total testosterone of 210 ng/dL (reference: 300 to 1000 ng/dL). His LH is 14.2 IU/L (reference: 1.5 to 8.5 IU/L), and his FSH is 11.8 IU/L.
The elevated LH indicates that the pituitary gland is functioning normally. It recognizes the low testosterone state and is sending a strong hormonal signal to the testes.
However, the Leydig cells are failing to respond adequately. During physical examination, the physician notes normal secondary sexual characteristics but slightly reduced testicular volume.
The physician identifies this as primary hypogonadism. Further investigation focuses on potential testicular causes, including a past history of severe physical trauma, viral orchitis, or environmental exposures.
Because the issue is located in the testes, treating the pituitary would not resolve the deficiency.
A 51-year-old man presents with low libido, mild erectile dysfunction, and brain fog. He has a body mass index (BMI) of 34 and mild obstructive sleep apnea. His morning fasting total testosterone is 175 ng/dL.
His LH returns at 2.8 IU/L, and his FSH is 3.1 IU/L.
At first glance, an LH of 2.8 IU/L might appear fine because it falls within the standard reference range. However, the clinician recognizes this as an inappropriately normal result. Given that his testosterone is severely depressed, a healthy pituitary should be generating a high LH output to stimulate production.
The physician identifies a secondary hypogonadism pattern. Because the total testosterone is below 150 ng/dL on repeat testing, the physician orders a serum prolactin test and evaluates pituitary health according to clinical practice guidelines.
The prolactin returns normal, suggesting no prolactinoma. The clinician determines that the patient's severe obesity, untreated sleep apnea, and metabolic inflammation are suppressing hypothalamic GnRH release.
Initial management focuses on continuous positive airway pressure (CPAP) therapy, nutritional changes, and structured exercise to restore central signaling.
A 29-year-old man and his partner have been unable to conceive after 14 months of unprotected intercourse. He has no symptoms of androgen deficiency, reporting normal energy, regular morning erections, and consistent muscle strength.
His total testosterone is 580 ng/dL, and his LH is 4.1 IU/L. However, his FSH is elevated at 15.4 IU/L.
This pattern reveals a clear divergence between androgen production and spermatogenesis. The patient's Leydig cells are producing ample testosterone under normal LH stimulation.
However, the elevated FSH suggests that Sertoli cells are not producing enough inhibin B, pointing toward a defect in the seminiferous tubules.
A formal semen analysis confirms severe oligospermia, showing a sperm concentration of less than 2 million per milliliter. The urologist orders genetic testing, including a karyotype and Y-chromosome microdeletion analysis, while conducting a detailed physical exam for a varicocele.
This case illustrates why normal testosterone levels do not guarantee normal fertility.
A 36-year-old man who has been taking prescribed intramuscular testosterone cypionate for nine months decides he wants to start a family. His recent lab panel shows a total testosterone of 720 ng/dL, an LH of less than 0.1 IU/L, and an FSH of less than 0.1 IU/L.
He expresses surprise that his sperm count is zero on a recent semen test, asking why high testosterone in his blood has not improved his fertility.
The clinician explains that circulating testosterone is not the same as intratesticular testosterone. The external testosterone has shut off his pituitary's production of LH and FSH through negative feedback.
Without LH, his Leydig cells produce no local testosterone, causing intratesticular concentrations to drop. Without FSH, his Sertoli cells cannot support sperm development.
The clinician guides him through a structured plan to discontinue TRT and consider alternative therapies to restore endogenous gonadotropin signaling before attempting conception.
A widespread misconception in male health is that circulating blood testosterone reflects reproductive fertility. Men often assume that if their total testosterone numbers are robust, their sperm count must be equally healthy.
Physiologically, androgen production and spermatogenesis are closely linked, but they are not interchangeable.
To produce healthy mature sperm, the concentration of testosterone within the testicular tissue must be 50 to 100 times higher than the concentration found in the general bloodstream.
This high local concentration is maintained by two factors:
When a man takes external testosterone, circulating blood levels rise. However, the resulting suppression of LH removes the stimulus for Leydig cells to produce local testosterone.
As a result, intratesticular testosterone drops precipitously, even while blood levels appear optimal. Without adequate local testosterone and FSH stimulation, Sertoli cells cannot sustain sperm maturation, leading to severe oligospermia or complete azoospermia.
Because blood tests cannot measure intratesticular hormone levels directly, serum markers serve only as indirect clues regarding fertility.
Guidelines from the American Urological Association (AUA) and the American Society for Reproductive Medicine (ASRM) emphasize that any man presenting with fertility concerns should undergo a comprehensive evaluation that includes both semen analysis and hormone testing. You can read more about these connections in our overview of testosterone, body, and sexual performance.
When evaluating hormone interactions, it is essential to distinguish established clinical guidelines from preliminary research and observational studies.
Leading professional medical societies, including the Endocrine Society, the American Urological Association (AUA), and the European Association of Urology (EAU), provide evidence-based recommendations for evaluating male hypogonadism and infertility.
While the core mechanics of the HPG axis are well established, other areas of research remain observational or subject to ongoing investigation:
Understanding these distinctions helps men approach their lab results with realistic expectations, avoiding commercial claims that promise simple fixes for complex regulatory systems.
Misinterpreting hormone panels is common among patients and non-specialist clinicians alike. Avoiding these frequent pitfalls ensures that diagnostic investigations remain accurate and safe.
As discussed earlier, a laboratory reference range represents a statistical distribution across a broad population, not a guarantee of appropriate function in an individual context.
If total testosterone is severely depressed, a normal-range LH is physiologically abnormal. Interpreting an in-range LH as healthy without considering the low testosterone result can cause clinicians to miss functional secondary hypogonadism or pituitary pathology.
An elevated FSH is an indicator of spermatogenic strain or damage to the seminiferous tubules. However, an elevated FSH does not prove that a man produces zero sperm.
Men with elevated FSH can sometimes achieve spontaneous conception, and many men with non-obstructive azoospermia and high FSH have focal areas of active spermatogenesis that can be identified through microdissection testicular sperm extraction (micro-TESE).
Testosterone levels fluctuate based on acute sleep deprivation, illness, intense physical stress, fasting status, and time of day.
A single reading below the reference threshold is never sufficient for a formal diagnosis. Guidelines strictly require repeat testing on separate mornings under fasting conditions before establishing hypogonadism. For more on this, visit our guide on low testosterone signs, causes, and risk factors.
Finding low gonadotropins alongside low testosterone can provoke anxiety about pituitary tumors.
While structural lesions must be ruled out when clinically indicated, the vast majority of secondary hypogonadism cases are functional. They are frequently caused by obesity, metabolic syndrome, chronic sleep apnea, medication side effects, or systemic stress.
Because testosterone is essential for male reproductive anatomy, some assume that taking testosterone medication will enhance fertility.
As established by physiological feedback mechanisms, external testosterone shuts down LH and FSH, suppressing natural sperm production. Men desiring future fertility must discuss alternative approaches with their doctor before starting any androgen therapy.
When meeting with a qualified physician, endocrinologist, or urologist to review hormone blood tests, having organized questions can help guide a productive conversation:
Revisit this guide whenever you receive updated hormone blood test results, undergo a fertility evaluation, or experience changes in clinical symptoms. It can also serve as a helpful reference before consultations with an endocrinologist or urologist to ensure you understand the biological mechanisms being discussed.
Understanding LH and FSH transforms isolated testosterone numbers into a coherent biological narrative, giving you the clarity needed to navigate your hormonal health alongside a qualified medical provider.
Testostra explains testosterone biology, testing, symptoms, lifestyle factors and TRT with careful sourcing and clear clinical limits.
Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra
